EGFR and head and neck squamous cell carcinoma: Overall, these data support the hypothesis that downstream effectors of the PI3K/Akt pathway serve as promising drug targets in the search for novel therapeutic combination strategies that are able to overcome resistance to anti-EGFR treatment in HNSCC patients.